SLASH: a program for analysing the functional groups in molecules.

D A Cosgrove; P Willett

doi:10.1016/s1093-3263(98)00014-x

Home/Archive/PubMed

PubMed · 9783257

SLASH: a program for analysing the functional groups in molecules.

D A Cosgrove·P Willett

View original source ↗Export metadata ↓

Abstract

The program SLASH, which is designed to enable large numbers of compounds to be analysed in terms of the functional groups they contain, is described. The usefulness of the groups for analysing the activities of compounds tested in high-throughput biological screens is investigated. The functional group fragments are also studied as a means of determining similarity within groups of compounds.

Explore related subjects

Drug Design Drug Evaluation, Preclinical Models, Chemical Molecular Structure Software Structure-Activity Relationship Comparative Study Journal Article Research Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

D A Cosgrove, P Willett. 1998. SLASH: a program for analysing the functional groups in molecules.. https://doi.org/10.1016/s1093-3263(98)00014-x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Kinetic analysis of the interaction between HIV-1 protease and inhibitors using optical biosensor technology.

The interaction between HIV-1 protease and reversible inhibitors was studied by surface plasmon resonance biosensor technology. The steady-state binding level and the time course of association and dissociation could be observed by measuring the binding of inhibitors injected in a continuous flow of buffer to the immobilized enzyme. Fourteen low molecular weight inhibitors (500-700 Da), including the four clinically used HIV-1 protease inhibitors (indinavir, nelfinavir, ritonavir, and saquinavir), were analyzed. Affinities were estimated as B(50) values from a series of sensorgrams at different concentrations of inhibitors. These values were found to be correlated with inhibition constants (K(i)) determined by an enzyme inhibition assay (r(2) = 0.84, logarithmic values). Dissociation rates were estimated at a single saturating concentration of the inhibitors as t(1/2,obs), but these values did not correlate with K(i) (r(2) = 0.26, logarithmic values). Indinavir had the highest affinity (B(50) = 11 nM) and the fastest dissociation (t(1/2,obs) = 500 s) among the clinically used inhibitors while saquinavir had a lower affinity (B(50) = 25 nM) and the slowest dissociation rate (t(1/2,obs) = 6500 s). Since these two inhibitors have similar K(i) values, the differences in dissociation rates reveal important characteristics in the interaction that cannot be obtained by the inhibition studies. The biosensor data are expected to be of greater in vivo relevance since the experiments were performed in a buffer more similar to physiological conditions.

Drug Design↗

PubMed2000

Soft drug design: general principles and recent applications.

Soft drug design represents a new approach aimed to design safer drugs with an increased therapeutic index by integrating metabolism considerations into the drug design process. Soft drugs are new therapeutic agents that undergo predictable metabolism to inactive metabolites after exerting their therapeutic effect. Hence, they are obtained by building into the molecule, in addition to the activity, the most desired way in which the molecule is to be deactivated and detoxified. In an attempt to systematize and summarize the related work done in a number of laboratories, including ours, the present review presents an overview of the general soft drug design principles and provides a variety of specific examples to illustrate the concepts. A number of already marketed drugs, such as esmolol, remifentanil, or loteprednol etabonate, resulted from the successful application of such design principles. Many other promising drug candidates are currently under investigation in a variety of fields including possible soft antimicrobials, anticholinergics, corticosteroids, beta-blockers, analgetics, ACE inhibitors, antiarrhythmics, and others. Whenever possible, pharmacokinetic and pharmacodynamic properties are briefly summarized and compared to those of other compounds used in the same field.

Drug Design↗

PubMed2000

Using photolabile ligands in drug discovery and development.

Photoactivatable ligands are important tools used in drug discovery and drug development. These ligands enable researchers to identify the targets of drugs, to determine the affinity and selectivity of the drug-target interaction, and to identify the binding site on the target. Examples are presented from three fundamentally different approaches: (1) photoaffinity labeling of target macromolecules; (2) photoactivation and release of 'caged ligands'; and (3) photoimmobilization of ligands onto surfaces.

Drug Design↗